GILD vs REPL · P/E 18, rev $29.44B vs $825.7M cap
Gilead Sciences Inc (GILD) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
REPL does not have a complete income-statement cache yet.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. REPL currently screens at market cap $825.7M.
Not investment advice. Open the GILD and REPL stock pages for the full models.
Not investment advice.